

### Company Overview

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and we may study other solid tumors, including ovarian cancer and pediatric CNS tumors.

### DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals

Jul 17 2020, 8:00 AM EDT

### DelMar Pharmaceuticals Receives \$500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

Jun 24 2020, 8:30 AM EDT

### DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly-Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II

Jun 22 2020, 8:30 AM EDT

### Stock Overview

Symbol	DMPI
Exchange	Nasdaq
Market Cap	10.93m
Last Price	\$0.9537
52-Week	\$0.38 - \$2.45

07/31/2020 04:00 PM EDT

### Investor Relations

T: (604) 629-5989  
[ir@delmarpharma.com](mailto:ir@delmarpharma.com)

### Management Team

#### Saïd Zarrabian

President and Chief Executive Officer, Director

#### Dennis M. Brown, Ph.D.

Chief Scientific Officer

#### Scott Prail, C.P.A.

Chief Financial Officer

### DelMar Pharmaceuticals, Inc.

12707 High Bluff Drive  
Suite 200  
San Diego, CA, United States, 92130

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.